LEIFRAS Co., Ltd. Reports Financial Results for the First Quarter of Fiscal Year 2026

LEIFRAS Co., Ltd. Reports Financial Results for the First Quarter of Fiscal Year 2026

Record High Revenue, Adjusted Income from Operations, and Net Income, Up 10.0%, 1.0%, and 1.5% Year-over-Year , Respectively [1] TOKYO, June 19, 2026 /PRNewswire/ -- LEIFRAS Co., Ltd. (Nasdaq: LFS) (the "Company" or "Leifras"), a sports and social...

Waterdrop Inc. Reports First Quarter 2026 Unaudited Financial Results, Q1 Net Revenue Up 64.8% Year-over-Year

Waterdrop Inc. Reports First Quarter 2026 Unaudited Financial Results, Q1 Net Revenue Up 64.8% Year-over-Year

BEIJING, June 16, 2026 /PRNewswire/ -- On June 16, 2026, Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with positive social impact, today announced its unaudited financial results for the...

Uxin Reports Unaudited Financial Results for the Quarter Ended March 31, 2026

Uxin Reports Unaudited Financial Results for the Quarter Ended March 31, 2026

BEIJING, June 16, 2026 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN), China's leading used car retailer, today announced its unaudited financial results for the quarter ended March 31, 2026. Highlights for the Quarter Ended...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. Post-hoc...

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

CAMBRIDGE, Mass. and TAIPEI, June 11, 2026 /PRNewswire/ -- Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmune diseases, today announced...

POP Culture Group Reports Stellar Half-Year Results: Robust Business Growth with Revenue Surging 141% Year-Over-Year

POP Culture Group Reports Stellar Half-Year Results: Robust Business Growth with Revenue Surging 141% Year-Over-Year

XIAMEN, China, June 10, 2026 /PRNewswire/ -- POP Culture Group Co., Ltd. (Nasdaq: CPOP, "POP Culture" or the "Company"), today announced its unaudited financial results for six months ended December 31, 2025. During the reporting period, the Company...

OceanaGold Reports Voting Results from its 2026 Annual Meeting of Shareholders

OceanaGold Reports Voting Results from its 2026 Annual Meeting of Shareholders

VANCOUVER, BC, June 10, 2026 /PRNewswire/ -- OceanaGold Corporation (TSX: OGC) (NYSE: OGC) ("OceanaGold" or the "Company") is pleased to report the voting results from the Annual General and Special Meeting of Shareholders of the Company (the "AGM")...

Acer Reports May Revenues at NT$26.17 Billion, a Record High in May in 13 Years, up 36.5% Year-on-year

Acer Reports May Revenues at NT$26.17 Billion, a Record High in May in 13 Years, up 36.5% Year-on-year

TAIPEI, June 9, 2026 /PRNewswire/ -- Acer Inc. (TWSE: 2353) announced its consolidated revenues for May at NT$26.17 billion with growth of 36.5% year-on-year (YoY). Consolidated revenues for year-to-May reached NT$129.91 billion with 31.0% growth...

Zepp Health Corporation Reports First Quarter of 2026 Unaudited Financial Results

Zepp Health Corporation Reports First Quarter of 2026 Unaudited Financial Results

MILPITAS, Calif., June 9, 2026 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP) today announced its unaudited financial results for the first quarter of 2026. First Quarter of 2026 Financial and Operating Highlights:...

Pictor® Reports Strong Commercial Momentum One Year After Launching U.S. Headquarters

Pictor® Reports Strong Commercial Momentum One Year After Launching U.S. Headquarters

The targeted proteomic platform company marks its first anniversary in Carlsbad with four commercial partnerships, seven products, BSL-2 equipped lab, and growing adoption across human and animal health markets globally CARLSBAD, Calif., June 2,...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 19
  • menu
    menu